Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients. [electronic resource]
Producer: 20170807Description: 526-534 p. digitalISSN:- 2146-8427
- Adult
- Antiviral Agents -- administration & dosage
- Cytomegalovirus -- drug effects
- Cytomegalovirus Infections -- diagnosis
- Drug Administration Schedule
- Female
- Ganciclovir -- administration & dosage
- Graft Rejection -- immunology
- Graft Survival -- drug effects
- Humans
- Immunocompromised Host
- Immunosuppressive Agents -- adverse effects
- Kidney Transplantation -- adverse effects
- Leukopenia -- chemically induced
- Male
- Middle Aged
- Opportunistic Infections -- diagnosis
- Risk Factors
- Time Factors
- Treatment Outcome
- Valganciclovir
- Virus Activation -- drug effects
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.